LOS ANGELES--(BUSINESS WIRE)--Goldberg Law PC, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Regulus Therapeutics Inc. (“Regulus” or the “Company”) (Nasdaq: RGLS). Investors who purchased or otherwise acquired Regulus shares between January 21, 2016 and June 27, 2016 inclusive (the “Class Period”), are encouraged to contact the firm in advance of the April 3, 2017 lead plaintiff motion deadline.
If you are a shareholder who suffered a loss during the Class Period, click here to participate. In addition, we encourage you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars, Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights free of charge. You can also reach us through the firm’s website at http://www.Goldberglawpc.com, or by email at email@example.com.
The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
The investigation concerns whether Regulus and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
On June 27, 2016, Regulus detailed that it was contacted by the U.S. Food and Drug Administration ("FDA") that its new drug to treat it chronic hepatitis C virus infection which was under FDA review, will now be put under clinical hold following a second intense case of jaundice.
On January 27, 2017, post-market, Regulus revealed that the FDA would not reconsider the clinical hold on RG-101 until the agency had received the last safety and efficacy data from continued clinical and pre-clinical studies. Regulus informed shareholders that it expects the required data to be available in the fourth quarter of 2017.
When this information was revealed to the investing public, the value of Regulus declined, causing investors severe harm.
Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.